PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för vactosertib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

10 hits

Bibliografisk träff 2023-02-28

Synthesis and biological evaluation of N-(3-fluorobenzyl)-4-(1-(methyl-d<sub>3</sub>)-1H-indazol-5-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-amine as a novel, potent ALK5 receptor inhibitor.

Kang BN, Kang HJ, Kim S, Lee J, Lee J, Jeong HJ, Jeon S, Shin Y, Yoon C, Han C, Seo J, Yun J.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2023.129205

Bibliografisk träff 2021-03-11

If small molecules immunotherapy comes, can the prime be far behind?

Zhang J, Zhang Y, Qu B, Yang H, Hu S, Dong X.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2021.113356

Bibliografisk träff 2021-02-23

Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5/p38α MAP inhibitors.

Liu YY, Guo Z, Wang JY, Wang HM, Da Qi J, Ma J, Piao HR, Jin CH, Jin X.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2021.113311

Bibliografisk träff 2020-02-18

Development of small molecule inhibitors targeting TGF-β ligand and receptor: Structures, mechanism, preclinical studies and clinical usage.

Wang H, Chen M, Sang X, You X, Wang Y, Paterson IC, Hong W, Yang X.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2020.112154

Bibliografisk träff 2019-07-09

Synthesis and biological evaluation of novel benzo[c][1,2,5]thiadiazol-5-yl and thieno[3,2-c]- pyridin-2-yl imidazole derivatives as ALK5 inhibitors.

Guo Z, Song X, Zhao LM, Piao MG, Quan J, Piao HR, Jin CH.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2019.07.015

Bibliografisk träff 2019-07-05

Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives.

Zhu WJ, Cui BW, Wang HM, Nan JX, Piao HR, Lian LH, Jin CH.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.07.013

Bibliografisk träff 2018-12-04

Targeting the immunity protein kinases for immuno-oncology.

Yuan X, Wu H, Bu H, Zhou J, Zhang H.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2018.11.072

Bibliografisk träff 2015-09-26

Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.

Krishnaiah M, Jin CH, Sheen YY, Kim DK.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2015.09.058

Bibliografisk träff 2014-05-13

Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.

Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Rao KS, Lee HJ, Park SJ, Park HJ, Lee K, Sheen YY, Kim DK.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm500115w

Bibliografisk träff 2014-03-21

4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.

Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Park HJ, Park SJ, Sheen YY, Kim DK.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2014.03.022